Chembio Diagnostics ROA 2006-2018 | CEMI

Current and historical return on assets (ROA) values for Chembio Diagnostics (CEMI) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Chembio Diagnostics ROA for the three months ending June 30, 2018 was -21.13%.
Chembio Diagnostics Annual ROA
2017 -38.35
2016 -64.87
2015 -11.52
2014 -4.55
2013 2.17
2012 5.43
2011 40.09
2010 27.66
2009 4.89
2008 -32.95
2007 -39.89
2006 -63.18
2005 -107.81
Chembio Diagnostics Quarterly ROA
Q2 2018 -5.87
Q1 2018 -2.28
Q4 2017 -12.03
Q3 2017 -3.04
Q2 2017 -11.09
Q1 2017 -7.74
Q4 2016 -12.43
Q3 2016 -9.43
Q2 2016 -65.78
Q1 2016 -1.51
Q4 2015 -3.12
Q3 2015 -1.92
Q2 2015 -2.82
Q1 2015 -2.69
Q4 2014 -1.98
Q3 2014 -1.13
Q2 2014 -0.61
Q1 2014 -0.96
Q4 2013 -1.07
Q3 2013 2.95
Q2 2013 -1.02
Q1 2013 1.82
Q4 2012 2.84
Q3 2012 -1.81
Q2 2012 1.85
Q1 2012 2.65
Q4 2011 36.68
Q3 2011 4.71
Q2 2011 2.31
Q1 2011 -1.85
Q4 2010 27.54
Q3 2010 2.22
Q2 2010 0.00
Q1 2010 -2.68
Q4 2009 3.44
Q3 2009 4.84
Q2 2009 1.78
Q1 2009 -5.71
Q4 2008 -9.31
Q3 2008 -3.66
Q2 2008 -5.84
Q1 2008 -12.07
Q4 2007 -9.47
Q3 2007 -10.56
Q2 2007 -9.12
Q1 2007 -10.00
Q4 2006 -13.03
Q3 2006 -23.90
Q2 2006 -24.18
Q1 2006 -32.10
Q4 2005 -30.66
Q3 2005 -24.84
Q2 2005 -20.77
Q1 2005 -12.07
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.135B $0.024B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $132.148B 20.26
Abbott Laboratories (ABT) United States $121.136B 25.39
Stryker (SYK) United States $65.261B 25.22
Boston Scientific (BSX) United States $52.233B 27.17
Baxter (BAX) United States $41.336B 28.14
Zimmer Biomet Holdings (ZBH) United States $26.744B 17.18
ResMed (RMD) United States $16.242B 32.25
Smith & Nephew SNATS (SNN) United Kingdom $16.130B 0.00
Canopy Growth (CGC) Canada $11.376B 0.00
Perrigo (PRGO) Ireland $10.065B 14.28
Bio-Rad Laboratories (BIO) United States $8.905B 57.18
Hill-Rom Holdings (HRC) United States $6.065B 20.57
Insulet (PODD) United States $6.029B 0.00
Haemonetics (HAE) United States $5.767B 52.63
ICU Medical (ICUI) United States $5.434B 36.82
Neogen (NEOG) United States $4.634B 73.73
GW Pharmaceuticals (GWPH) United Kingdom $4.582B 0.00
Agios Pharmaceuticals (AGIO) United States $4.266B 0.00
Hutchison China MediTech (HCM) China $3.798B 0.00
NuVasive (NUVA) United States $3.542B 33.60
National Vision Holdings (EYE) United States $3.271B 72.23
Quidel (QDEL) United States $2.532B 51.87
NxStage Medical (NXTM) United States $1.847B 0.00
Phibro Animal Health (PAHC) United States $1.708B 24.31
AtriCure (ATRC) United States $1.247B 0.00
Cardiovascular Systems (CSII) United States $1.233B 735.80
Omeros (OMER) United States $1.216B 0.00
VAREX IMAGING (VREX) United States $1.138B 18.60
Owens & Minor (OMI) United States $1.069B 11.44
PetIQ (PETQ) United States $1.069B 34.97
Eagle Pharmaceuticals (EGRX) United States $1.015B 29.95
Cerus (CERS) United States $0.985B 0.00
Surmodics (SRDX) United States $0.972B 117.42
MacroGenics (MGNX) United States $0.938B 0.00
OraSure Technologies (OSUR) United States $0.938B 61.32
TG Therapeutics (TGTX) United States $0.745B 0.00
Insys Therapeutics (INSY) United States $0.679B 0.00
LeMaitre Vascular (LMAT) United States $0.667B 32.00
Meridian Bioscience (VIVO) United States $0.642B 21.96
Lantheus Holdings (LNTH) United States $0.599B 18.63
Evolus (EOLS) United States $0.502B 0.00
NanoString Technologies (NSTG) United States $0.499B 0.00
Quanterix (QTRX) United States $0.427B 0.00
Cytosorbents (CTSO) United States $0.423B 0.00
Utah Medical Products (UTMD) United States $0.357B 22.97
Surface Oncology (SURF) United States $0.332B 0.00
BioLife Solutions (BLFS) United States $0.286B 0.00
Rockwell Medical (RMTI) United States $0.228B 0.00
Chimerix (CMRX) United States $0.191B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.172B 0.00
Fonar (FONR) United States $0.155B 7.73
Female Health (VERU) United States $0.099B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.085B 0.00
Trinity Biotech (TRIB) Ireland $0.082B 24.50
United-Guardian (UG) United States $0.076B 16.62
Neurotrope (NTRP) United States $0.066B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.059B 0.00
CAS Medical Systems (CASM) United States $0.057B 0.00
ImmuCell (ICCC) United States $0.049B 0.00
Capricor Therapeutics (CAPR) United States $0.033B 0.00
Valeritas Holdings (VLRX) United States $0.025B 0.00
Akers Biosciences Inc (AKER) United States $0.024B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.009B 0.00